HK1222122A1 - 選擇性藥物遞送組合物及使用方法 - Google Patents

選擇性藥物遞送組合物及使用方法

Info

Publication number
HK1222122A1
HK1222122A1 HK16110317.7A HK16110317A HK1222122A1 HK 1222122 A1 HK1222122 A1 HK 1222122A1 HK 16110317 A HK16110317 A HK 16110317A HK 1222122 A1 HK1222122 A1 HK 1222122A1
Authority
HK
Hong Kong
Prior art keywords
methods
drug delivery
delivery compositions
selective drug
selective
Prior art date
Application number
HK16110317.7A
Other languages
English (en)
Inventor
Jesus Gonzalez
Junjie Liu
Marcel Miampamba
Original Assignee
Avelas Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelas Biosciences Inc filed Critical Avelas Biosciences Inc
Publication of HK1222122A1 publication Critical patent/HK1222122A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16110317.7A 2013-04-22 2016-08-30 選擇性藥物遞送組合物及使用方法 HK1222122A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361814771P 2013-04-22 2013-04-22
PCT/US2014/035043 WO2014176284A1 (en) 2013-04-22 2014-04-22 Selective drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
HK1222122A1 true HK1222122A1 (zh) 2017-06-23

Family

ID=51792348

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110317.7A HK1222122A1 (zh) 2013-04-22 2016-08-30 選擇性藥物遞送組合物及使用方法

Country Status (4)

Country Link
US (3) US20160082119A1 (zh)
EP (1) EP2988786A4 (zh)
HK (1) HK1222122A1 (zh)
WO (1) WO2014176284A1 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2244741T3 (en) 2008-01-18 2015-05-26 Visen Medical Inc Fluorescent imaging agents
CA3026701C (en) 2009-03-02 2023-04-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
EP2686000B1 (en) 2011-03-15 2021-05-05 Massachusetts Institute of Technology Multiplexed detection with isotope-coded reporters
AU2012290318B2 (en) 2011-07-29 2016-09-01 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
CA3128911C (en) 2013-01-30 2023-10-17 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
CN118010994A (zh) 2013-06-07 2024-05-10 麻省理工学院 基于亲和力检测配体编码的合成性生物标记物
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
EP4176896A1 (en) 2014-01-31 2023-05-10 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US20190008983A1 (en) * 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
AU2016308290B2 (en) 2015-08-18 2022-04-14 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CN114681623A (zh) 2015-08-18 2022-07-01 乐天医药生技股份有限公司 酞菁染料偶联物的制造方法及稳定偶联物
DK3380487T3 (da) 2015-11-23 2020-12-07 Bristol Myers Squibb Co Additivsystemer til anvendelse i proteinpegylering
GB2545169B (en) * 2015-12-01 2019-10-09 Ellipses Pharma Ltd Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
CN114272389B (zh) 2016-03-02 2023-04-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
EP3440013A4 (en) 2016-04-08 2021-03-17 Massachusetts Institute of Technology METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES
WO2017184683A1 (en) * 2016-04-21 2017-10-26 The Board Of Regents Of The University Of Taxas System Methods and compositions for detecting aneurysms
CA3022928A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
RU2765098C2 (ru) * 2017-02-28 2022-01-25 Иммуноджен, Инк. Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
KR20200108002A (ko) 2018-01-08 2020-09-16 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 항체-접합체
WO2019204363A2 (en) * 2018-04-16 2019-10-24 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
CN108586562B (zh) * 2018-05-08 2019-09-06 苏州博源医疗科技有限公司 一种皮质醇衍生物及其制备方法与应用
US11377502B2 (en) 2018-05-09 2022-07-05 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US12049505B2 (en) 2018-12-06 2024-07-30 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
US20220226490A1 (en) * 2019-01-23 2022-07-21 R.P. Scherer Technologies, Llc Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates
EP3917528A4 (en) * 2019-01-28 2022-12-28 University of Rhode Island Board of Trustees TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS WITH PHLIP®
EP3930687A4 (en) * 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
MX2021011320A (es) 2019-03-19 2021-12-10 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Terapia de combinacion con omomyc y un anticuerpo que se une a pd-1 o a ctla-4 para el tratamiento del cancer.
TW202102272A (zh) 2019-03-29 2021-01-16 美商樂天醫藥生技股份有限公司 光免疫療法之方法及相關之生物標記
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
KR20230145031A (ko) * 2020-10-13 2023-10-17 아벨라스 애퀴지션 코포레이션 선택적 전달 분자의 사용 방법
JP2024503075A (ja) * 2021-01-15 2024-01-24 アール．ピー．シェーラー テクノロジーズ、エルエルシー 抗体－薬物コンジュゲートのための二重切断エステルリンカー
CN114522219B (zh) * 2022-02-23 2024-03-26 宜春学院 一种共递送聚合物前药及其制备方法和用途
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434810T2 (de) * 1993-11-16 2007-08-02 Bracco International B.V. Immobilisiertes markierungsverfahren
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
DK2244741T3 (en) * 2008-01-18 2015-05-26 Visen Medical Inc Fluorescent imaging agents
KR101095841B1 (ko) * 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
JP2012533560A (ja) * 2009-07-15 2012-12-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞における取り込みが制御可能なペプチド
US20130142734A1 (en) * 2010-01-12 2013-06-06 Ayelet David Targeted delivery systems for diagnostic applications
AU2012290318B2 (en) * 2011-07-29 2016-09-01 Avelas Biosciences, Inc. Selective delivery molecules and methods of use

Also Published As

Publication number Publication date
US20160082119A1 (en) 2016-03-24
EP2988786A4 (en) 2016-12-21
US20190374560A1 (en) 2019-12-12
EP2988786A1 (en) 2016-03-02
WO2014176284A1 (en) 2014-10-30
US20200376013A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
HK1222122A1 (zh) 選擇性藥物遞送組合物及使用方法
HK1226301A1 (zh) 修飾的治療劑及其組合物
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
IL244259A0 (en) Insertion of medical devices
HK1254909A1 (zh) 藥物納米粒子的傳送及其使用方法
IL240849A0 (en) Drug delivery devices and drug delivery method
IL286759A (en) Therapeutic methods and preparations
SG11201507294WA (en) Drug delivery devices with drug-permeable component and methods
HK1217720A1 (zh) 選擇性遞送分子及使用方法
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
SG11201507867RA (en) Antimicrobial compositions and methods of use
HK1220920A1 (zh) 治療性組合物和其用途
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
GB201314312D0 (en) Composition and delivery system
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
IL262252B (en) Medicinal compositions and processes involving mRNA transfection
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
EP2856259A4 (en) DISPOSAL DEVICES FOR BIOACTIVE AGENTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2983789A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
HK1219691A1 (zh) 醫藥組成物及其用途
HK1222543A1 (zh) 經口藥物遞送裝置和其使用方法
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
IL244537A0 (en) New administration preparations and methods of their use
GB201319437D0 (en) Delivery of drugs
EP3043721A4 (en) PHARMACOLOGICAL DELIVERY SYSTEMS AND ASSOCIATED METHODS